<?xml version='1.0' encoding='utf-8'?>
<document id="27725449"><sentence text="Evaluation of the Effects of S-Allyl-L-cysteine, S-Methyl-L-cysteine, trans-S-1-Propenyl-L-cysteine, and Their N-Acetylated and S-Oxidized Metabolites on Human CYP Activities."><entity charOffset="29-47" id="DDI-PubMed.27725449.s1.e0" text="S-Allyl-L-cysteine" /><entity charOffset="49-68" id="DDI-PubMed.27725449.s1.e1" text="S-Methyl-L-cysteine" /><entity charOffset="70-99" id="DDI-PubMed.27725449.s1.e2" text="trans-S-1-Propenyl-L-cysteine" /><pair ddi="false" e1="DDI-PubMed.27725449.s1.e0" e2="DDI-PubMed.27725449.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27725449.s1.e0" e2="DDI-PubMed.27725449.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s1.e0" e2="DDI-PubMed.27725449.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27725449.s1.e1" e2="DDI-PubMed.27725449.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s1.e1" e2="DDI-PubMed.27725449.s1.e2" /></sentence><sentence text="Three major organosulfur compounds of aged garlic extract, S-allyl-L-cysteine (SAC), S-methyl-L-cysteine (SMC), and trans-S-1-propenyl-L-cysteine (S1PC), were examined for their effects on the activities of five major isoforms of human CYP enzymes: CYP1A2, 2C9, 2C19, 2D6, and 3A4"><entity charOffset="12-24" id="DDI-PubMed.27725449.s2.e0" text="organosulfur" /><entity charOffset="59-77" id="DDI-PubMed.27725449.s2.e1" text="S-allyl-L-cysteine" /><entity charOffset="79-82" id="DDI-PubMed.27725449.s2.e2" text="SAC" /><entity charOffset="85-104" id="DDI-PubMed.27725449.s2.e3" text="S-methyl-L-cysteine" /><entity charOffset="106-109" id="DDI-PubMed.27725449.s2.e4" text="SMC" /><entity charOffset="116-145" id="DDI-PubMed.27725449.s2.e5" text="trans-S-1-propenyl-L-cysteine" /><entity charOffset="147-151" id="DDI-PubMed.27725449.s2.e6" text="S1PC" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e0" e2="DDI-PubMed.27725449.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e0" e2="DDI-PubMed.27725449.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e0" e2="DDI-PubMed.27725449.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e0" e2="DDI-PubMed.27725449.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e0" e2="DDI-PubMed.27725449.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e0" e2="DDI-PubMed.27725449.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e0" e2="DDI-PubMed.27725449.s2.e6" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e1" e2="DDI-PubMed.27725449.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e1" e2="DDI-PubMed.27725449.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e1" e2="DDI-PubMed.27725449.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e1" e2="DDI-PubMed.27725449.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e1" e2="DDI-PubMed.27725449.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e1" e2="DDI-PubMed.27725449.s2.e6" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e2" e2="DDI-PubMed.27725449.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e2" e2="DDI-PubMed.27725449.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e2" e2="DDI-PubMed.27725449.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e2" e2="DDI-PubMed.27725449.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e2" e2="DDI-PubMed.27725449.s2.e6" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e3" e2="DDI-PubMed.27725449.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e3" e2="DDI-PubMed.27725449.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e3" e2="DDI-PubMed.27725449.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e3" e2="DDI-PubMed.27725449.s2.e6" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e4" e2="DDI-PubMed.27725449.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e4" e2="DDI-PubMed.27725449.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e4" e2="DDI-PubMed.27725449.s2.e6" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e5" e2="DDI-PubMed.27725449.s2.e5" /><pair ddi="false" e1="DDI-PubMed.27725449.s2.e5" e2="DDI-PubMed.27725449.s2.e6" /></sentence><sentence text=" The metabolite formation from probe substrates for the CYP isoforms was examined in human liver microsomes in the presence of organosulfur compounds at 0"><entity charOffset="127-139" id="DDI-PubMed.27725449.s3.e0" text="organosulfur" /></sentence><sentence text="01-1 mM by using liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis" /><sentence text=" Allicin, a major component of garlic, inhibited CYP1A2 and CYP3A4 activity by 21-45% at 0"><entity charOffset="1-8" id="DDI-PubMed.27725449.s5.e0" text="Allicin" /></sentence><sentence text="03 mM" /><sentence text=" In contrast, a CYP2C9-catalyzed reaction was enhanced by up to 1" /><sentence text="9 times in the presence of allicin at 0"><entity charOffset="27-34" id="DDI-PubMed.27725449.s8.e0" text="allicin" /></sentence><sentence text="003-0" /><sentence text="3 mM" /><sentence text=" SAC, SMC, and S1PC had no effect on the activities of the five isoforms, except that S1PC inhibited CYP3A4-catalyzed midazolam 1'-hydroxylation by 31% at 1 mM"><entity charOffset="1-7" id="DDI-PubMed.27725449.s11.e0" text="SAC" /><entity charOffset="6-12" id="DDI-PubMed.27725449.s11.e1" text="SMC" /><entity charOffset="15-21" id="DDI-PubMed.27725449.s11.e2" text="S1PC" /><entity charOffset="86-92" id="DDI-PubMed.27725449.s11.e3" text="S1PC" /><pair ddi="false" e1="DDI-PubMed.27725449.s11.e0" e2="DDI-PubMed.27725449.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27725449.s11.e0" e2="DDI-PubMed.27725449.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s11.e0" e2="DDI-PubMed.27725449.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27725449.s11.e0" e2="DDI-PubMed.27725449.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27725449.s11.e1" e2="DDI-PubMed.27725449.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s11.e1" e2="DDI-PubMed.27725449.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27725449.s11.e1" e2="DDI-PubMed.27725449.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27725449.s11.e2" e2="DDI-PubMed.27725449.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27725449.s11.e2" e2="DDI-PubMed.27725449.s11.e3" /></sentence><sentence text=" The N-acetylated metabolites of the three compounds inhibited the activities of several isoforms to a varying degree at 1 mM" /><sentence text=" N-Acetyl-S-allyl-L-cysteine and N-acetyl-S-methyl-L-cysteine inhibited the reactions catalyzed by CYP2D6 and CYP1A2, by 19 and 26%, respectively, whereas trans-N-acetyl-S-1-propenyl-L-cysteine showed weak to moderate inhibition (19-49%) of CYP1A2, 2C19, 2D6, and 3A4 activities"><entity charOffset="1-28" id="DDI-PubMed.27725449.s13.e0" text="N-Acetyl-S-allyl-L-cysteine" /><entity charOffset="33-61" id="DDI-PubMed.27725449.s13.e1" text="N-acetyl-S-methyl-L-cysteine" /><entity charOffset="155-193" id="DDI-PubMed.27725449.s13.e2" text="trans-N-acetyl-S-1-propenyl-L-cysteine" /><pair ddi="false" e1="DDI-PubMed.27725449.s13.e0" e2="DDI-PubMed.27725449.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27725449.s13.e0" e2="DDI-PubMed.27725449.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s13.e0" e2="DDI-PubMed.27725449.s13.e2" /><pair ddi="false" e1="DDI-PubMed.27725449.s13.e1" e2="DDI-PubMed.27725449.s13.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s13.e1" e2="DDI-PubMed.27725449.s13.e2" /></sentence><sentence text=" On the other hand, both the N-acetylated and S-oxidized metabolites of SAC, SMC, and S1PC had little effect on the reactions catalyzed by the five isoforms"><entity charOffset="72-109" id="DDI-PubMed.27725449.s14.e0" text="SAC" /><entity charOffset="77-114" id="DDI-PubMed.27725449.s14.e1" text="SMC" /><entity charOffset="86-123" id="DDI-PubMed.27725449.s14.e2" text="S1PC" /><pair ddi="false" e1="DDI-PubMed.27725449.s14.e0" e2="DDI-PubMed.27725449.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27725449.s14.e0" e2="DDI-PubMed.27725449.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s14.e0" e2="DDI-PubMed.27725449.s14.e2" /><pair ddi="false" e1="DDI-PubMed.27725449.s14.e1" e2="DDI-PubMed.27725449.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s14.e1" e2="DDI-PubMed.27725449.s14.e2" /></sentence><sentence text=" These results indicated that SAC, SMC, and S1PC have little potential to cause drug-drug interaction due to CYP inhibition or activation in vivo, as judged by their minimal effects (IC50&gt;1 mM) on the activities of five major isoforms of human CYP in vitro"><entity charOffset="30-33" id="DDI-PubMed.27725449.s15.e0" text="SAC" /><entity charOffset="35-38" id="DDI-PubMed.27725449.s15.e1" text="SMC" /><entity charOffset="44-47" id="DDI-PubMed.27725449.s15.e2" text="S1PC" /><pair ddi="false" e1="DDI-PubMed.27725449.s15.e0" e2="DDI-PubMed.27725449.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27725449.s15.e0" e2="DDI-PubMed.27725449.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s15.e0" e2="DDI-PubMed.27725449.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27725449.s15.e1" e2="DDI-PubMed.27725449.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27725449.s15.e1" e2="DDI-PubMed.27725449.s15.e2" /></sentence><sentence text="" /></document>